Eidogen-Sertanty Expands Kinase Structure-Activity Database

The Most Comprehensive Database of
Annotated Kinase Modulators Available

San Diego, CA (July 26, 2005) – Eidogen-Sertanty, Inc., a computational drug discovery solutions provider, today announced that it has significantly increased the size of its Kinase Knowledgebase (KKB), a structure-activity and chemistry database focused on kinase modulators. The KKB now contains over 390,000 unique kinase molecules and over 160,000 quality-checked SAR data points mined from over 1,900 journal articles and patents. Eidogen-Sertanty’s systematic compilation of kinase data focuses on kinase targets of high pharmaceutical interest, such as receptor tyrosine kinases, cell division kinases, and kinases involved in disease-relevant signal transduction pathways.

Data in the KKB is standardized and classified to facilitate the development of computational QSAR models for virtual screening, and to enable medicinal chemists to easily map out patent space and synthetic strategies for kinase discovery programs. The Kinase Knowledgebase is released quarterly and has a growth rate of over 50,000 SAR data points and over 90,000 unique structures per year.

About the Kinase Knowledgebase
The Kinase Knowledgebase (KKB) is Eidogen-Sertanty's database of structure-activity relationships and chemical synthesis data focused on protein kinases—one of the most therapeutically important classes of drug targets. Kinase SAR data points and molecules are mined from scientific literature and patents and classified by target name and assay type, along with chemical synthesis protocols and additional in vitro and animal model efficacy data when applicable.

The Kinase Knowledgebase is designed to support medicinal chemists during all stages of kinase drug discovery projects. At the start of a project, the KKB provides an overview of published knowledge and patents around kinase targets of therapeutic importance , enabling a detailed understanding of the knowledge space around the target of interest and the relevant anti-targets. The presentation of inhibitor structural data makes it easy to group known inhibitors in scaffold groups and lay out a project plan around patentable chemotypes.

In the lead discovery and optimization phase of a project, the knowledgebase helps to prioritize compounds for synthesis or purchas e based on their predicted properties. The well-curated SAR data is also extremely useful for the development of proprietary QSAR models for virtual screening. Using the high quality SAR content, Eidogen-Sertanty has developed nearly 50 kinase-specific eScreen® modules for important kinase targets useful for potency and selectivity prediction and lead optimization.

The KKB can either be accessed online through Eidogen-Sertanty’s ARK™ platform or licensed for integration into in-house databases. To learn more about the Kinase Knowledgebase and to request a demonstration, please visit http://www.eidogen-sertanty.com/products_kinasekb.html.

Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their suite of products and services please visit www.eidogen-sertanty.com.

Contact Information:
Steven Muskal
760-729-0211
pr@eidogen-sertanty.com.